RXRX
Recursion Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-25
Figures on this page computed 2026-11-08 13:05 UTC
Last close
3.88USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-25
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-25
-133.9%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
-863.4%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
-506.5%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
0.09Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-11-02
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Margins is the furthest below its sector's middle: 0.06 against 0.36 on the market's range.
- Growth79.9%62 of 100, above its sector
- Returns on capital-133.9%11 of 100, below its sector
- Margins5.0%6 of 100, below its sector
- Price1.4x32 of 100, below its sector
- Safety0.0963 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 2 of 3- Profit on each unit of sales-863%-639%Behind
Higher is better here.
- Return on the capital it uses-134%n/an/a
Higher is better here.
- Sales growth over five years79.9%-2.1%Ahead
Higher is better here.
- Debt against equity0.09n/an/a
Lower is better here.
- Gross margin5.0%100.0%Behind
Higher is better here.
- Price against earningsn/an/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Vir Biotechnology, Inc., RXRX is behind on 2 of 3 measures.
Against Vir Biotechnology, Inc., RXRX is behind on 2 of 3 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-25
Profit on each unit of sales-863.4%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD
Return on the capital it uses-133.9%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD
Sales growth over five years79.9%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD
Debt against equity0.09
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD
Gross margin5.0%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD
Price against earningsn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001601830-26-000039
- Reported in
- USD